Gilead To Pay $8M To Settle Viread Securities Action
By Mike Cherney ( July 8, 2010, 6:27 PM EDT) -- Gilead Sciences Inc. has agreed to pay $8.25 million to settle a securities class action alleging the biopharmaceutical company artificially inflated its stock price by failing to disclose that high sales for its flagship HIV drug Viread were due to illegal off-label marketing....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.